Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
In a study of 50 younger patients with new AML or high risk MDS treated at MDA, CLIA + VEN showed a 95% rate of CR+CRi and a 1 year OS of 85%. 1 patient died during induction and and 2 died of infectious consolidation during consolidation, all of whom were on FLT inhibitors as well.
